Literature DB >> 10065635

T-cell response in human leishmaniasis.

A Kharazmi1, K Kemp, A Ismail, S Gasim, A Gaafar, J A Kurtzhals, A M El Hassan, T G Theander, M Kemp.   

Abstract

In the present communication we provide evidence for the existence of a Th1/Th2 dichotomy in the T-cell response to Leishmania antigens in human leishmaniasis. Our data suggest that the pattern of IL-4 and IFN-gamma response is polarised in these patients. Lymphocytes from individuals recovered from cutaneous leishmaniasis (CL) responded by IFN-gamma production following stimulation with Leishmania antigens whereas cells from patients recovered from visceral leishmaniasis (VL) showed a mixed pattern of IFN-gamma and IL-4 responses. The cells producing these cytokines were predominantly CD4+. Furthermore, IL-10 plays an important role in the development of post kala azar dermal leishmaniasis (PKDL) from VL. The balance between the parasitic-specific T-cell response plays an important regulatory role in determining the outcome of Leishmania infections in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065635     DOI: 10.1016/s0165-2478(98)00132-1

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  19 in total

1.  Dichotomy of protective cellular immune responses to human visceral leishmaniasis.

Authors:  E A G Khalil; N B Ayed; A M Musa; M E Ibrahim; M M Mukhtar; E E Zijlstra; I M Elhassan; P G Smith; P M Kieny; H W Ghalib; F Zicker; F Modabber; A M Elhassan
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

2.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

4.  Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.

Authors:  Katharina Kronenberg; Sven Brosch; Florian Butsch; Yayoi Tada; Naotaka Shibagaki; Mark C Udey; Esther von Stebut
Journal:  J Invest Dermatol       Date:  2010-06-24       Impact factor: 8.551

5.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

6.  A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.

Authors:  Vivian T Martins; Mariana C Duarte; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Cecília S P Coelho; Danielle F de Magalhães-Soares; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasit Vectors       Date:  2015-07-11       Impact factor: 3.876

7.  Association of interleukin-18 gene variants with susceptibility to visceral leishmaniasis in Iranian population.

Authors:  Ali Moravej; Manoochehr Rasouli; Sadaf Asaei; Mehdi Kalani; Yaser Mansoori
Journal:  Mol Biol Rep       Date:  2012-12-27       Impact factor: 2.316

8.  Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Authors:  Sanchita Datta; Madhumita Manna; Supriya Khanra; Moumita Ghosh; Radhaballav Bhar; Anindita Chakraborty; Syamal Roy
Journal:  Parasitol Res       Date:  2012-03-23       Impact factor: 2.383

9.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.